За матеріалами телемосту «Невиношування: сучасні аспекти ведення вагітності, важливі кроки від зачаття до народження здорової дитини»

ESHRE Guideline Group on RPL; Bender AR, Christiansen OB, Elson J, Kolte AM, Lewis S, et al. ESHRE guideline: Recurrent pregnancy loss: an update in 2022. Hum Reprod Open. 2023;2023(1):hoad002. doi: 10.1093/hropen/hoad002.

Arora M, Bashiri A, Mukhopadhyay N. Recurrent pregnancy loss. 4th Edition. Jaypee Brothers Medical Publishers (P) Ltd; 2025. 529 p.

Bashiri A, Harlev A, Agarwal A. Recurrent Pregnancy Loss. Evidence-Based Evaluation, Diagnosis and Treatment [Internet]. 4th Edition. Springer Cham; 2016. 208 p. Available from: https://doi.org/10.1007/978-3-319-27452-2.

Schlaikjær HT, Ambye L, Gruhn JR, Petersen JF, Wrønding T, Amato L, et al. Cell-free fetal DNA for genetic evaluation in Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study. Lancet. 2023;401(10378):762-71. doi: 10.1016/S0140-6736(22)02610-1.

Peuranpää PL, Gissler M, Peltopuro P, Tiitinen A, Hautamäki H. The effect of paternal and maternal factors on the prognosis of live birth in couples with recurrent pregnancy loss. Acta Obstet Gynecol Scand. 2022;101(12):1374-85. doi: 10.1111/aogs.14469.

Coomarasamy A, Devall AJ, Brosens JJ, Quenby S, Stephenson MD, Sierra S, et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstet Gynecol. 2020;223(2):167-76. doi: 10.1016/j.ajog.2019.12.006.

Du Fossé NA, van der Hoorn MP, van Lith JMM, le Cessie S, Lashley EELO. Advanced paternal age is associated with an increased risk of spontaneous miscarriage: a systematic review and meta-analysis. Hum Reprod Update. 2020;26(5):650-69. doi: 10.1093/humupd/dmaa010.

McQueen DB, Zhang J, Robins JC. Sperm DNA fragmentation and recurrent pregnancy loss: a systematic review and meta-analysis. Fertil Steril. 2019;112(1):54-60.e3. doi: 10.1016/j.fertnstert.2019.03.003.

Bashiri A, Giliutin M, Ziedenberg H, Plakht Y, Baumfeld Y. A proposed prognostic prediction tool for a live birth among women with recurrent pregnancy loss. J Matern Fetal Neonatal Med. 2022;35(19):3736-42. doi: 10.1080/14767058.2020.1839877.

Kolte AM, Westergaard D, Lidegaard Ø, Brunak S, Nielsen HS. Chance of live birth: a nationwide, registry-based cohort study. Hum Reprod. 2021;36(4):1065-73. doi: 10.1093/humrep/deaa326.

Andersen LB, Dechend R, Karumanchi SA, Nielsen J, Joergensen JS, Jensen TK, et al. Early pregnancy angiogenic markers and spontaneous abortion: an Odense Child Cohort study. Am J Obstet Gynecol. 2016;215(5):594.e1-e11. doi: 10.1016/j.ajog.2016.06.007.

Hou W, Yan XT, Bai CM, Zhang XW, Hui LY, Yu XW. Decreased serum vitamin D levels in early spontaneous pregnancy loss. Eur J Clin Nutr. 2016;70(9):1004-8. doi: 10.1038/ejcn.2016.83.

Nagwa AE, Fadeel A, Nabil Aboushady RM, Soliman HF. Association between Vitamin D deficiency and occurrence of miscarriage among women. IOSR J Nursing Health Sci. 2019;8(3):53-62. doi: 10.9790/1959-0803055362.

Wang L-Q, Yan X-T, Yan C-F, Zhang X-W, Hui L-Y, Xue M, et al. Women with recurrent miscarriage have decreased expression of 25-Hydroxyvitamin D3-1α-Hydroxylase by the

fetal-maternal interface. PLoS ONE. 2016;11(12):e0165589. doi: 10.1371/journal.pone.0165589.

Zhang BY, Wei YS, Niu JM, Li Y, Miao ZL, Wang ZN. Risk factors for unexplained recurrent spontaneous abortion in a population from southern China. Int J Gynaecol Obstet. 2010;108(2):135-8. doi: 10.1016/j.ijgo.2009.09.019.

Boots C, Stephenson MD. Does obesity increase the risk of miscarriage in spontaneous conception: a systematic review. Semin Reprod Med. 2011;29(6):507-13. doi: 10.1055/s-0031-1293204.

Stefanidou EM, Caramellino L, Patriarca A, Menato G. Maternal caffeine consumption and sine causa recurrent miscarriage. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):220-4. doi: 10.1016/j.ejogrb.2011.04.024.

Maconochie N, Doyle P, Prior S,

Simmons R. Risk factors for first

trimester miscarriage--results from a UK-population-based case-control study. BJOG. 2007;114(2):170-86. doi: 10.1111/j.1471-0528.2006.01193.x.

Cavalcante MB, Sarno M, Peixoto AB, Araujo JE, Barini R. Obesity and recurrent miscarriage: A systematic review and meta-analysis. J Obstet Gynaecol Res. 2019;45(1):30-8. doi: 10.1111/jog.13799.

Metwally M, Saravelos SH, Ledger WL,

Li TC. Body mass index and risk of miscarriage in women with recurrent miscarriage. Fertil Steril. 2010;94(1):290-5. doi: 10.1016/j.fertnstert.2009.03.021.

Sugiura-Ogasawara M. Recurrent pregnancy loss and obesity. Best Pract Res Clin Obstet Gynaecol. 2015;29(4):489-97. doi: 10.1016/j.bpobgyn.2014.12.001.

Bashir M, Fagier Y, Ahmed B, C Konje J. An overview of diabetes mellitus in pregnant women with obesity. Best Pract Res Clin Obstet Gynaecol. 2024;93:102469. doi: 10.1016/j.bpobgyn.2024.102469.

Bodnar LM, Simhan HN, Powers RW, Frank MP, Cooperstein E, Roberts JM. High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. J Nutr. 2007;137(2):447-52. doi: 10.1093/jn/137.2.447.

Huang HY, Chen HL, Feng LP. Maternal obesity and the risk of neural tube defects in offspring: A meta-analysis. Obes Res Clin Pract. 2017;11(2):188-97. doi: 10.1016/j.orcp.2016.04.005.

US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, et al. Screening for prediabetes and type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(8):736-43. doi: 10.1001/jama.2021.12531.

Yassaee F, Mostafaee L. The role of cervical cerclage in pregnancy outcome in women with uterine anomaly. J Reprod Infertil. 2011;12(4):277-9.

Leo L, Arduino S, Febo G, Tessarolo M, Lauricella A, Wierdis T, et al. Cervical cerclage for malformed uterus. Clin Exp Obstet Gynecol. 1997;24(2):104-6.

Golan A, Langer R, Wexler S, Segev E, Niv D, David MP. Cervical cerclageits role in the pregnant anomalous uterus. Int J Fertil. 1990;35(3):164-70.

Rikken JFW, Kowalik CR, Emanuel MH, Bongers MY, Spinder T, Jansen FW, et al. Septum resection versus expectant management in women with a septate uterus: an international multicentre open-label randomized controlled trial. Hum Reprod. 2021;36(5):1260-67. doi: 10.1093/humrep/deab037.

Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N Engl J Med. 2019;380(19):1815-24. doi: 10.1056/NEJMoa1813730.

Ku CW, Allen JC Jr, Lek SM, Chia ML, Tan NS, Tan TC. Serum progesterone distribution in normal pregnancies compared to pregnancies complicated by threatened miscarriage from 5 to 13 weeks gestation: a prospective cohort study. BMC Pregnancy Childbirth. 2018;18(1):360. doi: 10.1186/s12884-018-2002-z.

Bashiri A, Galperin G, Zeadna A, Baumfeld Y, Wainstock T. Increased live birth rate with dydrogesterone among patients with recurrent pregnancy loss regardless of other treatments. J Clin Med. 2023;12(5):1967. doi: 10.3390/jcm12051967.

Shehata H, Elfituri A, Doumouchtsis SK, Zini ME, Ali A, Jan H, et al. FIGO Good Practice Recommendations on the use of progesterone in the management of recurrent first-trimester miscarriage. Int J Gynaecol Obstet. 2023;161(1):3-16. doi: 10.1002/ijgo.14717.

Tetruashvili N, Domar A, Bashiri A. Prevention of Pregnancy loss: combining progestogen treatment and psychological support. J Clin Med. 2023;12(5):1827. doi: 10.3390/jcm12051827.

Zhao Y, D’Souza R, Gao Y, Hao Q, Kallas-Silva L, Steen JP, et al. Progestogens in women with threatened miscarriage or recurrent miscarriage: A meta-analysis. Acta Obstet Gynecol Scand. 2024;103(9):1689-701. doi: 10.1111/aogs.14829.

Pang YY, Ma CL. Real-world pharmacological treatment patterns of patients with threatened miscarriage in China from 2014 to 2020: A cross-sectional analysis. J Clin Pharm Ther. 2022;47(2):228-36. doi: 10.1111/jcpt.13536.

Arab H, Alharbi AJ, Oraif A, Sagr E, Al Madani H, Abduljabbar H, et al. The role of progestogens in threatened and idiopathic recurrent miscarriage. Int J Womens Health. 2019;11:589-96. doi: 10.2147/IJWH.S224159.

Mashiach S. Recurrent pregnancy loss: causes, controversies, and treatment. Isr Med Assoc J. 2021;23(1):64-5.

Zhao H, He W, Yang Z. A pairwise and network meta-analysis comparing the efficacy and safety of progestogens in threatened abortion. Int J Gynaecol Obstet. 2022;156(3):383-93. doi: 10.1002/ijgo.13707.

Kale AR, Kale AA, Yelikar K. A Comparative, randomized control trial in patients of per vaginal bleeding comparing efficacy of oral dydrogesterone versus vaginal progesterone in successful pregnancy outcome for patients with recurrent pregnancy loss. J Obstet Gynaecol India. 2021;71(6):591-5. doi: 10.1007/s13224-021-01473-2.

Zhang HX, Qin YZ, Liu WH, Hao R. Hypothyroidism and first-trimester spontaneous miscarriages. Clin Exp Obstet Gynecol. 2014;41(2):182-5.

El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol

Biol. 2005;97(5):431-4. doi: 10.1016/j.jsbmb.2005.08.007.

Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009;65(1):47-50. doi: 10.1016/j.maturitas.2009.11.016.

Tomic V, Tomic J, Klaic DZ, Kasum M, Kuna K. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;186:49-53. doi: 10.1016/j.ejogrb.2014.11.002.

Tournaye H, Sukhikh GT, Kahler E, Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017;32(5):1019-27. doi: 10.1093/humrep/dex023.

Griesinger G, Blockeel C, Kahler E,

Pexman-Fieth C, Olofsson JI, Driessen S, et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. PLoS One. 2020;15(11):e0241044. doi: 10.1371/journal.pone.0241044.

El Hachem H, Crepaux V, May-Panloup P, Descamps P, Legendre G, Bouet PE. Recurrent pregnancy loss: Current perspectives. Int J Womens Health. 2017;9:331-45. doi: 10.2147/IJWH.S100817.

Qiao J. Clinical practice guidelines for progesterone in pregnancy maintenance and luteal phase support. Chin J Reprod Contracept. 2021;41:95-105. doi: 10.3760/cma.j.cn101441-20200930-00543.

TSOP guidelines. 1st version, second edition.TOBE; 2021.

National Institute for Health and Care Excellence. Ectopic pregnancy and miscarriage: diagnosis and initial management [Internet]. NICEguideline [NG126]. 2019. Available from: https://www.nice.org.uk/guidance/NG126.

Brent RL. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol. 2005;73(11):906-18. doi: 10.1002/bdra.20184.

Dailey J, Rosman L, Silbergeld EK. Evaluating biological plausibility in supporting evidence for action through systematic reviews in public health. Public Health. 2018;165:48-57. doi: 10.1016/j.puhe.2018.08.015.

Katalinic A, Noftz MR, Garcia-Velasco JA, Shulman LP, van den Anker JN, Strauss Iii JF. No additional risk of congenital anomalies after first-trimester dydrogesterone use: a systematic review and meta-analysis. Hum Reprod Open. 2024;2024(1):hoae004. doi: 10.1093/hropen/hoae004.

Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016;32(2):97-106. doi: 10.3109/09513590.2015.1121982.

Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev. 2009;85(6):375-7. doi: 10.1016/j.earlhumdev.2008.12.016.

Podzolkova N, Tatarchuk T, Doshchanova A, Eshimbetova G, Pexman-Fieth C. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol Endocrinol. 2016;32(3):246-9. doi: 10.3109/09513590.2015.1115832.

Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009;65(1):3-11. doi: 10.1016/j.maturitas.2009.10.011.

Regulatory directive documents of the Ministry of Health of Ukraine. Instructions for medical use of Duphaston® [Internet]. 2012. Available from: https://mozdocs.kiev.ua/likiview.php?id=30976.

Simoncini T, Caruso A, Giretti MS, Scorticati C, Fu XD, Garibaldi S, et al. Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril. 2006;86(4):1235-42. doi: 10.1016/j.fertnstert.2006.05.018.

Divakova ТS, Famina МР. Effects of dydrogesterone and acetylsalicylic acid on placental angiogenesis in complicated pregnancies. Med J. 2014;(2):3.

Abdel-Razik M, El-Berry S, Mostafa A. The effects of nitric oxide donors on uterine artery and sub-endometrial blood flow in patients with unexplained recurrent abortion. J Reprod Infertil. 2014;15(3):142-6.

Quenby S, Gallos ID, Dhillon-Smith RK, PodesekM, Stephenson MD, Fisher J, et al. Miscarriage matters: The epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet. 2021;397(10285):1658-67. doi: 10.1016/S0140-6736(21)00682-6.

Revankar S. Miscarriage statistics by risk percentage, country, demographics and facts [Internet]. Coolest Gadgets; 2025. Available from: https://www.coolest-gadgets.com/miscarriage-statistics/.

Vorobyova II, Zhivetskaya-Denisova AA, Tkachenko VB, Rudakova NV, Tolkach SM. Miscarriage of pregnancy: Current views on the problem (literature review). Health Wo­man. 2017;3(119):113-7.

Vovk IB, Vdovichenko YP, Trokhimovich OV, Zadorozhna TD, Gorovenko NG. Early reproductive expenses. Kyiv; 2016. 253 p.

National Institute for Strategic Research. Socio-demographic situation in Ukraine: the paths of the heirs of the war [Internet]. 2022. Available from: https://niss.gov.ua/news/komentari-ekspertiv/sotsialno-demohrafichna-sytuatsiya-v-ukrayini-shlyakhy-podolannya.

NoBrainer Data. The Demographic Tragedy of Ukraine: A Second Holodomor? [Internet]. 2022. Available from: https://nobrainerdata.com/2022/06/17/the-demographic-tragedy-of-ukraine-a-se-

cond-holodomor/.

International Federation of Gynecology and Obstetrics. What is the psychological impact of miscarriage? [Internet]. FIGO; 2018. Available from: https://www.figo.org/news/what-psychological-impact-miscarriage.

Toth B, Würfel W, Bohlmann M, Zschocke J, Rudnik-Schöneborn S, et al. Recurrent miscarriage: diagnostic and therapeutic procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/050). Geburtshilfe Frauenheilkd. 2018;78(4):364-81. doi: 10.1055/a-0586-4568.

Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol. 2012;28(12):983-90. doi: 10.3109/09513590.2012.702875.

Wahabi HA, Fayed AA, Esmaeil SA, Bahkali KH. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2018;8(8):CD005943. doi: 10.1002/14651858.CD005943.pub5.

Wang XX, Luo Q, Bai WP. Efficacy of progesterone on threatened miscarriage: Difference in drug types. J Obstet Gynaecol Res. 2019;45(4):794-802. doi: 10.1111/jog.13909.

Li L, Zhang Y, Tan H, Bai Y, Fang F, Faramand A, et al. Effect of progestogen for women with threatened miscarriage: a systematic review and meta-analysis. BJOG. 2020;127(9):1055-63. doi: 10.1111/1471-0528.16261.

Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administra-

tion. Climacteric. 2005;8(1):3-63. doi: 10.1080/13697130500148875.

Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2008;61(1-2):171-80. doi: 10.1016/j.maturitas.2008.11.013.

Morrill GA, Kostellow AB, Askari A.

Progesterone binding to the alpha1-

subunit of the Na/K-ATPase on the cell surface: insights from computational modeling. Steroids. 2008;73(1):27-40. doi: 10.1016/j.steroids.2007.08.012.

PharmaCompass. Dydrogesterone CEP granted [Internet]. Available from: https://www.pharmacompass.com/certificates-of-suitability-products-cep/dydrogesterone.

European Pharmacopoeia. Certificate of Suitability No. R0-CEP 2019-114-Rev 00. Dydrogesterone [Internet]. European Pharmacopoeia; 2019. Available from: https://www.lgcstandards.com/DE/en/search?text=Dydrogesterone.

European Pharmacopoeia. Dydrogesterone No 07/2022:2357 [Internet]. European Pharmacopoeia; 2022. Available from: https://www.lgcstandards.com/DE/en/search?text=Dydrogesterone.

The United States Pharmacopoeia USP Certificate. Dydrogesterone [Internet]. USP Template No CERT1-07. 2021. Available from: https://www.usp.org/reference-standards.

Stanczyk FZ, HapgoodJP, Winer S,

MishellDR. Progestogens used in postmenopausal hormone therapy: Differen-

ces in their pharmacological properties, intracellular actions, and clinical effects. EndocrRev. 2013;34(2):171-208.

Paulson RJ, Collins MG, Yankov VI. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. J Clin Endocrinol Metab. 2014;99(11):4241-9. doi: 10.1210/jc.2013-3937.

Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(1):7-16. doi: 10.1016/j.maturitas.2003.09.014.

Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2008;61(1-2):171-80. doi: 10.1016/j.maturitas.2008.11.013.

Rižner TL, Brožič P, Doucette C, Turek-Etienne T, Müller-Vieira U, Sonneveld E, et al. Selectivity and potency of the retro progesterone dydrogesterone in vitro. Steroids. 2011;76(6):607-15. doi: 10.1016/j.steroids.2011.02.043.

State register of medicinal products of Ukraine. Instructions for medical

administration of medicinal progesterone, micronized 100 mg or 200 mg. [Internet]. Available from: http://www.drlz.com.ua/.

Kamga YM, Ngunde JP, Akoa-

chere JKT. Prevalence of bacterial vaginosis and associated risk factors in pregnant women receiving antenatal care at the Kumba Health District (KHD), Cameroon. BMC Pregnancy Childbirth. 2019;19(1):166. doi: 10.1186/s12884-019-2312-9.

Mengistie Z, Woldeamanuel Y, Asrat D, Adera A. Prevalence of bacterial vaginosis among pregnant women attending antenatal care in Tikur Anbessa University Hospital, Addis Ababa, Ethiopia. BMC ResNotes. 2014;7:822. doi: 10.1186/1756-0500-7-822.

Faruqui А Bacterial Vaginosis: Risk of adverse pregnancy outcome. J GynecolRes Obstet. 2018;4(2):15-7. doi: 10.17352/jgro.000051.

Patki A, Pawar VC. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol. 2007;23(1):68-72. doi: 10.1080/09513590701584857.

Ganesh A, Chakravorty N, Mukhe-

rjee R, Goswami S, Chaudhury K, Chakravarty B. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril. 2011;95(6):1961-5. doi: 10.1016/j.fertnstert.2011.01.148.

Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol. 2005;97(5):416-20. doi: 10.1016/j.jsbmb.2005.08.012.

Katalinic А, Shulman LP, Strauss JF, Garcia-Velasco JA, van den Anker JN. А critical appraisal of safety data on dydrogesterone for the support of early pregnancy: а scoping review and meta-analysis. Reprod Віomed OnІіne. 2022;45(2):365-73. doi: 10.1016/j.rbmo.2022.03.032.

Cumming GP, Klein S, Bolsover D, Lee AJ, Alexander DA, Maclean M, et al. The emotional burden of miscarriage for women and their partners: trajectories of anxiety and depression over 13

months. BJOG. 2007;114(9):1138-45. doi: 10.1111/j.1471-0528.2007.01452.x.